Does Medicare cover GLP-1s for weight loss in 2026?
This article is for general education only. It is not medical advice, and it is not a substitute for a consultation with a licensed physician. Treatment decisions, including whether any medication is appropriate for you, are made by a licensed physician after reviewing your health history.
Yes. Starting July 1, 2026, Medicare's GLP-1 Bridge covers Wegovy, Zepbound KwikPen, and Foundayo for weight loss at a flat $50 monthly copay for Part D enrollees who meet specific BMI and health criteria.
This is a genuine first. Since the Part D benefit was created, federal law has excluded drugs prescribed purely for weight loss, so Medicare enrollees paid full price for Wegovy or Zepbound unless they had a separately covered diagnosis. The GLP-1 Bridge, a CMS demonstration that grew out of the November 2025 pricing deals with Novo Nordisk and Eli Lilly, changes that from July 1, 2026 through December 31, 2027. It covers the injectable and pill forms of Wegovy (semaglutide), Foundayo (orforglipron, Eli Lilly's once-daily pill approved April 1, 2026), and the KwikPen form of Zepbound (tirzepatide) at $50 per month, the same copay at every dose.
The Bridge is not ordinary Part D coverage. It runs through a separate CMS system with its own prior authorization, and roughly 3.8 million Part D enrollees could meet the criteria, per a KFF analysis reported by AARP. Meanwhile, regular Part D continues to cover GLP-1s for type 2 diabetes, cardiovascular risk reduction, and obstructive sleep apnea under normal plan rules. The longer-term plan, the BALANCE Model, was indefinitely delayed on the Medicare side in April 2026 after weak insurer participation, which is why CMS extended the Bridge through the end of 2027.
Who qualifies for the $50 Medicare GLP-1 Bridge?
Eligibility is based on BMI plus specific health conditions, in three tiers. A BMI of 35 or higher meets the criteria on its own. A BMI of 30 to 34 requires one of: chronic kidney disease (stage 3a or above), heart failure with preserved ejection fraction, or high blood pressure that remains uncontrolled on two or more medications. A BMI of 27 to 29 requires prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease.
Three conditions are deliberately excluded as qualifiers: type 2 diabetes, moderate to severe obstructive sleep apnea, and fatty liver disease (MASH). That is because regular Part D already covers GLP-1s for those diagnoses. You also need to be enrolled in Medicare drug coverage, and your prescriber must attest the medication is for weight reduction alongside diet and exercise. Whether the Bridge fits your situation is a conversation for your own physician, who confirms the clinical details CMS requires.
How do you actually get a GLP-1 through the Bridge?
Your prescriber submits a prior authorization request to a CMS-run system, not to your Part D plan. CMS targets a 72-hour turnaround, and once approved you pay the flat $50 at the pharmacy regardless of dose or benefit phase. Refills do not need a new authorization unless you switch medications.
The covered products are specific: Wegovy in both injectable and tablet form, Foundayo tablets, and only the KwikPen formulation of Zepbound. Ozempic, Mounjaro, and Rybelsus are not on the Bridge list because their FDA approvals are for diabetes, not weight management.
What is the catch with the $50 copay?
The main catch is that Bridge spending sits outside your normal Part D protections. The $50 copays do not count toward your deductible or the $2,100 annual out-of-pocket cap for 2026 (rising to $2,400 in 2027). Extra Help (the low-income subsidy) does not reduce the copay, and you cannot spread Bridge costs through the Medicare Prescription Payment Plan. If something goes wrong, you deal with Medicare directly rather than your plan.
It is also temporary. The Bridge ends December 31, 2027, and the successor BALANCE Model was indefinitely postponed for Medicare in April 2026, so coverage after 2027 is an open question. Plan for that uncertainty rather than assuming the $50 rate is permanent.
Does regular Medicare Part D still cover Ozempic or Mounjaro?
Yes, for medically accepted uses other than weight loss. Part D plans cover Ozempic, Mounjaro, Rybelsus, and similar drugs for type 2 diabetes under normal formulary rules. Wegovy is covered for cardiovascular risk reduction in adults with established heart disease plus overweight or obesity, and Zepbound is covered for moderate to severe obstructive sleep apnea with obesity.
Those prescriptions flow through your plan's regular cost-sharing, and unlike Bridge copays, the spending does count toward the $2,100 out-of-pocket cap. For weight loss alone outside the Bridge criteria, the statutory exclusion still applies and Medicare pays nothing.
What if you do not qualify, or you are not on Medicare?
You still have cash-pay routes, and prices have dropped since the 2025 manufacturer deals. Eli Lilly's Foundayo starts at $149 per month self-pay at the lowest dose as of 2026, a price that covers the medication itself, not any prescribing visit, and manufacturers sell directly through LillyDirect, NovoCare, and the government's TrumpRx site. Prices scale with dose on most direct-purchase programs.
Cash-pay telehealth is another path. Sipra's membership is $99/mo with unlimited physician visits, and weight loss medication starts at $79/mo, priced by plan length rather than dose, with no charge until a physician approves and full cost disclosed before checkout. Availability varies by state. Telehealth prescribing rules, pharmacy options, and specific medications differ depending on where you live. Physicians typically consider GLP-1s for adults with BMI 30+, or 27+ with a weight-related condition, per the FDA labels; the GLP-1 eligibility calculator at /calculators/glp-1-eligibility can help you map those criteria before a visit.
Medicare GLP-1 coverage in 2026, by situation
| Your situation | What Medicare covers | What you pay |
|---|---|---|
| Weight loss, meets Bridge criteria | Wegovy (pill or injection), Foundayo, Zepbound KwikPen | $50/month flat, July 1, 2026 through Dec 31, 2027 |
| Type 2 diabetes | Ozempic, Mounjaro, Rybelsus via regular Part D | Plan cost-sharing; counts toward $2,100 cap |
| Heart disease plus overweight/obesity | Wegovy via regular Part D (cardiovascular indication) | Plan cost-sharing; counts toward cap |
| Obstructive sleep apnea with obesity | Zepbound via regular Part D | Plan cost-sharing; counts toward cap |
| Weight loss, does not meet Bridge criteria | Nothing (statutory exclusion still applies) | Full self-pay price |
Bridge copays do not count toward the Part D deductible or the $2,100 out-of-pocket cap (2026), and Extra Help does not apply to them.
Bottom line
For the first time, Medicare pays for GLP-1s prescribed purely for weight loss, but only through the Bridge demonstration: three drugs, a flat $50 monthly copay, and coverage that runs only through December 2027 for people who fit the BMI and condition tiers.
If you are on Medicare, ask your prescriber whether you meet the Bridge criteria and have them submit the prior authorization. If you do not qualify, compare direct-purchase and telehealth self-pay routes carefully, because total monthly cost varies widely by channel.
Check your GLP-1 eligibilityMore questions, answered
Does Medicaid cover GLP-1s for weight loss in 2026?
In some states. The BALANCE Model's Medicaid track began May 1, 2026 and runs through 2031, letting participating states cover GLP-1s for obesity at negotiated prices. State participation is voluntary, so coverage depends on whether your state opted in. Check your state Medicaid agency for its current status.
Is Ozempic covered for weight loss under the Bridge?
No. Ozempic is not one of the three Bridge medications, and regular Part D covers it only for type 2 diabetes. The Bridge is limited to drugs FDA-approved for weight management: Wegovy, Foundayo, and the KwikPen form of Zepbound. A physician can discuss which covered option fits your situation.
Can Medicare Advantage members use the GLP-1 Bridge?
Yes, if the plan includes drug coverage. The Bridge is open to anyone enrolled in Medicare prescription drug coverage, whether through a standalone Part D plan or a Medicare Advantage plan with drug benefits (MA-PD). The prior authorization goes through the CMS Bridge system rather than through the plan itself.
Related questions
Lose weight with a plan made just for you
- Same-day doctor visits and prescriptions
- Semaglutide, tirzepatide & other GLP-1s
- FSA & HSA eligible with all plans
*Price includes medication only. Active $99/mo Sipra membership required.
Was this helpful?